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Background: Oxidative and nitrosylative changes have been shown to occur in conjunction with the hypoxic
changes and cellular/axonal damage in hydrocephalic rodent brains. We hypothesized that antioxidant therapy
would improve behavioral, neurophysiological, and/or neurobiochemical outcomes in juvenile rats following
induction of hydrocephalus.
Methods: Three-week old rats received an injection of kaolin (aluminum silicate) into the cisterna magna. Magnetic
resonance (MR) imaging was performed two weeks later to assess ventricle size and stratify rats to four treatment
conditions. Rats were treated for two weeks daily with sham therapy of either oral canola oil or dextrose or
experimental therapy of a low or high dose of an antioxidant mixture containing α-tocopherol, L-ascorbic acid,
coenzyme Q10 (CoQ10), reduced glutathione, and reduced lipoic acid. Behavior was examined thrice weekly.
Results: All hydrocephalic groups lagged in weight gain in comparison to non-hydrocephalic controls, all developed
significant ventriculomegaly, and all exhibited white matter destruction. Canola oil with or without the antioxidant
mixture normalized antioxidant capacity in brain tissue, and the dextrose-treated rats had the greatest ventricular
enlargement during the treatment period. However, there were no significant differences between the four treatment
groups of hydrocephalic rats for the various behavioral tasks. Glial fibrillary acidic protein and myelin basic protein
quantitation showed no differences between the treatment groups or with control rats. There was increased lipid
peroxidation in the hydrocephalic rats compared to controls but no differences between treatment groups.
Conclusion: The antioxidant cocktail showed no therapeutic benefits for juvenile rats with kaolin-induced hydrocephalus
although canola oil might have mild benefit.
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Hydrocephalus is a neurological condition in which
altered cerebrospinal fluid (CSF) flow dynamics lead to
expansion of ventricular cavities in the brain. The neuro-
pathophysiological damage associated with hydrocephalus
is multifactorial with mechanical factors and reduced white
matter blood flow simultaneously contributing to axonal
and oligodendroglial damage [1,2]. Hypoxic changes in
proteins of white matter glial and endothelial cells have
been found in hydrocephalic rats using immunohisto-
chemical detection of pimonidazole [3]. Oxidative stress* Correspondence: marc.delbigio@med.umanitoba.ca
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unless otherwise stated.leads to cell damage in various neurodegenerative dis-
orders, including Parkinson disease, Alzheimer disease,
Huntington disease, amyotrophic lateral sclerosis, and
multiple sclerosis [4-8]. Lipid peroxidation, which follows
oxygen free radical damage to cell membranes, has been
shown in rodent hydrocephalic brains by measuring
malondialdehyde (MDA) levels using the biochemical
assay of thiobarbituric acid reaction substances (TBARS)
[3,9-11] and a lipid peroxidation assay kit [12]. Immuno-
histochemical detection of MDA and 4-hydroxy-2-
nonenal (4-HNE) [3] and superoxide dismutase (SOD)
[13] and a fluorometric assay for reactive oxygen spe-
cies (ROS), using dichlorofluorescein fluorescence
[12], have also shown evidence of oxidation in hydro-
cephalic rat brain tissue.al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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shunting, where CSF is diverted to another body site
[14]. Although early CSF shunting shows some benefits in
restoring periventricular white matter damage and cere-
bral blood flow, axonal damage is irreversible [1,2,15,16].
Moreover, treatment by shunting is associated with fre-
quent complications, particularly obstruction and infec-
tion in young infants, which add to its morbidity and
mortality [17,18]. With such potential complications,
current methods of treatment need improvement, which
warrants the need for novel therapeutic interventions to
supplement shunt surgeries. In the juvenile rat model,
parenteral administration of nimodipine or magnesium
sulfate [19,20] and continuous intraventricular infusion of
decorin [21] has some protective value. Experimental
hydrocephalus was induced by kaolin (aluminum silicate)
injections into the cisterna magna at 3 weeks in the rats in
these and other studies in our laboratory [3,22-24] because
the rat brain at this age is developmentally similar to that
of a human infant [25-27].
Because oxidative stress is associated with brain dam-
age in hydrocephalus, antioxidant therapy has been
considered a potential pharmacological treatment for
this condition. N-acetylcysteine [10] and the main con-
stituent of green tea polyphenols, epigallocatechin gallate
[11] have been shown to reduce lipid peroxidation
when injected daily into the peritoneum of rats with
experimentally-induced hydrocephalus at 7 days and
3 weeks, respectively. Antioxidants have shown benefi-
cial outcomes in treating other neurological disorders. In
particular, oral coenzyme Q10 (CoQ10) dietary supple-
mentation in humans and animals is found to reduce
oxidative stress by decreasing lipid peroxidation and
may be a neuroprotectant in Parkinson disease, athero-
sclerosis, ischemia, toxic brain injury, and Alzheimer
disease [28,29]. Alpha/gamma tocopherol (vitamin E)
added to drinking water has been shown to reduce brain
infarct volume after middle cerebral artery occlusion
focal ischemia in rats [30] and is functionally interrelated
with other antioxidants, including CoQ10, ascorbic acid,
glutathione, and lipoic acid [31]. Oral treatment with the
combination of α-lipoic acid and vitamin E can decrease
lipid peroxidation and astroglial and microglial reactivity
in the cerebrum of ischemic rats [32]. Oral CoQ10 and
ascorbic acid (vitamin C) have been used to enhance
oxidative phosphorylation in patients with mitochondrial
disorders [33]. These antioxidant agents alone and in
combination have low toxicity and have been shown to
be of potential value in animal and human studies when
given orally. Thus, we hypothesized that oral treatment
with a combination of these antioxidant agents would
lead to behavioral and/or structural improvements in
rats induced with experimental hydrocephalus using
kaolin injections.Methods
Animals
Locally bred Sprague–Dawley (Trial 1, n = 45) and Long
Evans rats (Trial 2, n = 52) were housed in conventional
cages with four animals per cage. Pelleted food and
water were provided ad libitum. The housing room was
kept on a 12:12 h (6 a.m. – 6 p.m.) light–dark cycle, and
the room temperature was 21–23°C. For identification,
the rats were ear punched. All animals were treated
humanely in accordance with guidelines set forth by the
Canadian Council on Animal Care. The University of
Manitoba Bannatyne Campus (Animal) Protocol Man-
agement & Review Committee approved the experimen-
tal protocols.Hydrocephalus induction
At 21–23 days of age (weight 42-88 g) rats were anesthe-
tized using 3% isoflurane in oxygen. The back of the
neck was shaved, the skin was cleaned with chlorhexi-
dine followed by 70% alcohol, and then a sterile 27-
gauge needle (shallow bevel “blunt” tip) was inserted
percutaneously into the cisterna magna. A sterile sus-
pension of kaolin (aluminum silicate, 250 mg/mL;
Sigma, St. Louis MO) in 0.9% normal saline (0.04 mL)
was injected slowly to induce hydrocephalus (n = 89).
Littermate controls (n = 8) received sham injections of
sterile saline solution. Following recovery from the
anesthetic, the rats were observed for signs of neurological
impairment. Subcutaneous buprenorphine (0.03 mg/kg)
was administered every 12 hours for 2 days to control
pain. Rats were weighed daily. Those experiencing severe
impairment or weight loss >15% of the starting weight
were euthanized.Magnetic resonance imaging and assignment to
treatment groups
T2–weighted magnetic resonance imaging (MRI) was
performed as previously described [20,22] on day 13 or
14 post injection. The ventricle to brain area ratio was
performed using computerized planimetry with Marevisi
(NRC, Winnipeg, MB, Canada) and Image J software on
a coronal image of the cerebrum just caudal to the optic
chiasm. The size of frontal horn of the lateral ventricles
was calculated by dividing the area of the ventricles by
the area of the cerebrum. Rats were stratified according
to ventricle size and assigned listwise to vehicle sham,
dextrose sham, low dose, or high dose dietary interven-
tion treatment groups. A second set of MR images was
obtained 2 weeks later, no more than 24 hours prior to
euthanasia. For each rat, the ventricle to brain area ratio
was measured again and compared to the images
obtained prior to treatment to determine the relative
change in ventricle size within treatment groups.
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The antioxidant therapy was performed separately with
two trials of rats (n = 45 and n = 52, respectively). The
treatment procedures were the same for both trials
except where indicated. All animals were weighed daily,
and their weights were used to determine treatment
volumes. The rats received these calculated dosages daily
for two weeks by oral gavage to ensure that all animals
consumed the entire dosage. Daily gavage with 1 ml
saline was started 1 week prior to kaolin injection so
that the rats were habituated to the intervention. The
rats in the first trial received their oral treatment in the
late afternoon after all behavioral testing was completed,
whereas the rats in the second trial received their treat-
ment in the early morning before any behavioral testing
was performed.
A combination of antioxidant agents shown to be effect-
ive in a variety of neurological disease models was chosen.
Alpha-tocopherol (Sigma T3251) at 50 and 250 mg/kg,
L-ascorbic acid (Sigma A7506) at 20 and 100 mg/kg
[34,35], CoQ10 (Sigma C9538) at 40 and 200 mg/kg [31],
reduced glutathione (Sigma G4251) at 20 and 100 mg/kg
[36], and reduced lipoic acid (Sigma T8260) at 20 and
100 mg/kg [37] provided the antioxidant ingredients for
the low and high dose concentrations, respectively.
These were made up in a mixture of 0.45% saline with
30% canola oil. Ingredients were blended thoroughly at
room temperature and stored in dark containers at 4°C.
In the first trial, the control rats received saline solu-
tion with 5% dextrose added to make up for the calo-
ries in the treatment groups. In addition, because of
supply problems, the first trial rats received the reduced
lipoic acid only during the first week. For the second
trial, the low and high doses were made up separately
and stored in different containers. The control hydro-
cephalic rats received a 0.20 mL/100 g volume of either
saline solution with 5% dextrose or the vehicle of 30%
canola oil (which was also given to nonhydrocephalic
controls).
Behavioral testing
All behavioral testing was completed in a blinded man-
ner. The rats performed various tests including mobility,
stance, and gait in the open field, gait on a rotarod at
steady and accelerating speed, swim speed in a narrow
pool, memory in a modified water maze test as assessed
previously [19,20,22], and gait on a modified ladder test
[38]. They were always tested in the same order, where
open field and rotarod tests were done on one day, the
ladder test on the next day, and the water-related tasks
on the third day weekly. Testing began the same week of
kaolin and sham injections and was performed for
4 weeks, i.e., during the 2 weeks after injections and the
2 weeks of antioxidant or sham therapy. During the firsttrial, all quantitative behavioral measurements were ob-
tained by manual timing using a stopwatch only. For the
second trial, water maze behavior was videotaped and
analyzed using HVS Image 2100 Plus Tracking System
software (HVS Image Ltd, Twickenham, Middlesex, UK).
The ladder test was only performed during the second
trial.Histopathological and biochemical studies following drug
treatments
Rats were euthanized within 24 hours of final MR im-
aging using isoflurane anesthesia (5%) followed by car-
bon dioxide gas narcosis and exsanguination. Blood was
flushed by transcardiac perfusion with ice-cold 0.1 M
phosphate-buffered saline (PBS), and the brains quickly
removed. Cerebral hemispheres were split in the midline.
The left side was divided into dorsal frontal cerebrum,
dorsal parietal cerebrum, hippocampus, and cerebellum
then frozen in liquid nitrogen and stored at −70°C. The
right side was immersion fixed in cold 3% buffered para-
formaldehyde and after 3–5 days was cut coronally, dehy-
drated, and embedded in paraffin wax.
Paraffin sections (6 μm thickness) of the cerebrum at
the level of the anterior horn of the lateral ventricles
were stained with hematoxylin & eosin Y (H&E) and
solochrome cyanine & eosin for visualization of myelin.
Sections were immunostained with rabbit polyclonal
anti-glial fibrillary acidic protein (GFAP) (1:12800 dilution;
DAKO Z0334; Glostrup, Denmark) to label astrocytes.
The primary antibody underwent 1–2 hour incubation
at room temperature. This was followed by incubation
with appropriate biotinylated secondary antibody, fol-
lowed by reaction with streptavidin-peroxidase, detec-
tion with diaminobenzidine (DAB, Sigma D5905), and
finally counterstaining with hematoxylin. Negative con-
trols were treated without the primary antibody. Corpus
callosum thickness was measured using 400x ocular
magnification at the sagittal midline and above the lat-
eral angle of the frontal horn of the lateral ventricle
medial to the external capsule. The latter site was chosen
because the midline region was often disrupted preventing
proper measure and comparison to nonhydrocephalic
animals.
Frozen frontal and parietal cerebrum samples were
homogenized using a RIPA buffer with protease inhibi-
tors phenylmethylsulfonyl fluoride (PMSF) and aproti-
nin. Total protein quantification was performed using
the Micro BCA™ (Pierce) Protein Assay kit (Thermo
Scientific, Rockford, Illinois, USA). Homogenates were
used to quantitate myelin basic protein (MBP) and
GFAP by using enzyme-linked immunosorbent assays
(ELISA), as previously described in detail [39,40]. Assays
were performed in triplicate. Results for the first trial are
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dilutions, while the second trial averaged results per sample.
TBARS and total antioxidant assays
Lipid peroxidation was measured to determine if hydro-
cephalic rat brains had increased oxidative byproduct
formation. Dorsal frontal and parietal cerebrum homog-
enates (second trial only) were tested using the thio-
barbituric acid reactive substances (TBARS) assay at
pH 3.5; TBA reacts with malondialdehyde (MDA), which
is a secondary product of lipid peroxidation, yielding a
product that can be detected spectrophotometrically at
532 nm [3,41]. The assay was performed as previously
described with a few modifications, and samples were run
in triplicate. The standard, 1′1′3′3 tetramethoxypropane
(TMP) (Sigma Cat #108383), was dissolved initially with
dimethyl sulfoxide (DMSO) to 1 M concentration and
then diluted in distilled water to 2.5-50 μM. In addition, 1-
butanol and pyridine were not added after heating the
TBA solution at 95°C for one hour, as the TBA and MDA
red pigmented reaction product was evident during the
heating process.
The Antioxidant Assay Kit (Sigma Cat #CS0790) was
used to measure total antioxidant levels in brain tissue
(second trial only). The frozen hippocampus was mech-
anically homogenized in ice-cold 1x Assay Buffer as
instructed (Sigma Cat # A3605). The assay is based on
the reaction between hydrogen peroxide (H2O2) and met-
myoglobin; the ferryl myoglobin radical oxidizes 2,2′-
azino-bis (3-ethylbenzthiazoline-6-sulfonic acid) (ABTS)
to form a radical cation (ABTS+), which is detected by
spectrophotometry at 405 nm. Samples were run in
duplicate.
Statistical analysis
Unless otherwise stated, all data are presented as mean ±
standard error of the mean (SEM). Quantitative data were
analyzed to confirm a normal distribution. For all analyses,
p values ≤ 0.05 were deemed statistically significant.
Statistical analyses were conducted separately for the
first (n = 45) and second (n = 52) trials of rats, which
consisted of ANOVA with post-hoc analyses conducted
for some measures using the Bonferroni-Dunn multiple
inter-group comparisons approaches where indicated.
Non-parametric score data were analyzed with Mann–
Whitney U test or Kruskal-Wallis test for two or three
groups, respectively. For the second trial, qualitative
assessments for the sham control and hydrocephalic rats
were analyzed separately from quantitative measures. Two-
tailed Student’s t-tests were conducted for behavioral
testing, ventricle size, histological data, biochemical, and
ELISA values to compare the control and hydrocephalus
groups. Statistical analyses were conducted using the
SPSS 14.0 software program.Results
Mortality
No animals died during kaolin injection. Of the 89 rats
that were given a kaolin-injection at three weeks age, 4
were euthanized approximately two weeks post-injection
before the onset of therapy and 1 died 2 days before the
end of treatment because of severe neurological deficits.
The remaining rats underwent the two-week antioxidant
therapy regime according to the stratification of treat-
ment conditions and were sacrificed at seven weeks of
age. Age-matched control rats (n = 8) were also eutha-
nized at seven weeks age and 24 hours post-MRI.
Ventricle size on magnetic resonance imaging
The first MR images showed that kaolin injections into
the cisterna magna lead to dilatation of the cerebral
ventricles in five-week old rats (Figure 1). In both trials,
there was no significant difference between the groups
prior to onset of antioxidant therapy. All groups showed
continued enlargement of the ventricles during the
therapeutic period, and all groups displayed significant
increases in lateral ventricle size compared to the images
before treatment began (all p < 0.05, t-tests; Tables 1 and
2; Figure 2). In the first trial, the high dose treatment
groups had the most severe ventricular enlargement
with a 33.5% increase after treatment (Table 1). In the
second trial, the low and high dose groups showed less
ventricular enlargement than dextrose control (p = 0.012
and 0.041, respectively), but there was no benefit above
canola oil vehicle-treated hydrocephalic rats (Table 2).
Behavioral assessments
Hydrocephalic rats gained less weight than nonhydroce-
phalic rats. They had hunched posture and unsteady gait
on open field observations (as previously reported), al-
though the quantitative measures of motor behavior only
inconsistently showed deficits, the most obvious being
reduced rearing activity (Table 2). In trial 1, there were
no differences in the behavioral outcomes of hydroceph-
alic rats following 2 weeks of low or high dose anti-
oxidant therapy compared to dextrose controls (Table 1).
Post-hoc analyses showed that the high dose antioxidant
treatment group displayed higher ambulatory movement
compared to sham-treated rats after therapy that was
approaching significance (p = 0.0575, Bonferroni test).
In the second trial, the four hydrocephalic treatment
groups all weighed significantly less than nonhydroce-
phalic rats from 24 days of age to when they were sacri-
ficed at 49 days of age (all p < 0.01, t-tests; ANOVA;
Table 2). Despite the fact that the dextrose fed hydroceph-
alic controls had more severe ventricle enlargement, they
tended to show greater weight gain. Only rearing behavior
was significantly reduced as a consequence of hydroceph-
alus before treatment compared to nonhydrocephalic
Figure 1 Magnetic resonance (MR) images displaying progressive hydrocephalus in rats at 5 and 7 weeks of age that underwent
injection of kaolin into the cisterna magna at 3 weeks. These T2-weighted images depict the coronal view of the cerebral cortex at the level
of the frontal horn of the lateral ventricle where cerebrospinal fluid (CSF) is white (bright) in the lateral and third ventricles and subarachnoid space (SAS).
The control rat images are shown at the top, and the ventricles are very narrow. Ventricular enlargement is obvious in all hydrocephalic rats before
treatment, and all treated groups displayed further dilatation after treatment.
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evidence for normalization of behavior abnormalities
(ambulation, water maze, ladder test) associated with
hydrocephalus following any of the treatments (Table 2).
Structural and biochemical changes in brain
Histological examination corresponded to the MR im-
aging. There was appreciable thinning and fragmentation
of periventricular white matter regions in all hydroceph-
alic animals. Corpus callosum thickness was significantly
reduced overall in the hydrocephalic rats compared to
control animals (p = 0.005, ANOVA). The lateral corpuscallosum had more pronounced (32%) decrease in thick-
ness (Table 2) than the medial corpus callosum (22%),
and it was significantly reduced in all treatment groups
compared to nonhydrocephalic controls (all p < 0.005,
t-tests). Cortical and subcortical neuronal populations
were not obviously damaged in the hydrocephalic rats
compared to controls, unless the adjacent white matter
was completely obliterated. Antioxidant therapy had no
effect on corpus callosum thickness. Although the cor-
pus callosum was thinned, overall the cerebral MBP
content (relative to total protein) was not reduced as a
consequence of hydrocephalus suggesting that surviving
Table 1 Results of antioxidant treatment on hydrocephalic rats (Trial 1)*
Dextrose Low dose antiox.† High dose antiox.†
Sample size 14 14 15
Ventricle area index (pre-treat) 0.130 ± 0.010 0.128 ± 0.008 0.145 ± 0.021
Ventricle area index (post-treat) 0.141 ± 0.012# 0.138 ± 0.009# 0.198 ± 0.039#
Percent enlargement ventricles during treatment 9.3 ± 3.1 8.6 ± 2.0 33.5 ± 18.7
Body weight (g) (pre-treat) 106.1 ± 2.4 103.7 ± 1.1 106.6 ± 3.3
Body weight (g) (post-treat) 223.8 ± 4.5 223.1 ± 3.2 222.8 ± 7.0
Rearing activity (post-treat) (beam breaks in 5 min) 108 ± 18 146 ± 18 166 ± 26
Ambulatory activity (post-treat) (beam breaks in 5 min) 760 ± 85 824 ± 87 1284 ± 221
Total activity (post-treat) (beam breaks in 5 min) 1089 ± 107 1210 ± 107 1684 ± 248
Endurance of rotarod (cont. speed, post-treat) (sec) 60 ± 12 64 ± 11 44 ± 11
Endurance of rotarod (accelerating speed, post-treat) (sec) 21 ± 6 27 ± 6 25 ± 8
Morris water maze test (post-treat, 3 trials mean) (sec) 15.98 ± 1.21 15.17 ± 1.82 33.86 ± 12.17
Swim time 150 cm (post-treat) (sec) 11.98 ± 1.31 16.45 ± 1.87 14.31 ± 1.78
GFAP content (ELISA) frontal cerebrum (mg GFAP/g protein) 1.30 ± 0.13 1.54 ± 0.31 1.56 ± 0.32
MBP content (ELISA) frontal cerebrum (mg MBP/g protein) 5.19 ± 0.19 5.31 ± 0.12 5.24 ± 0.25
All data are presented as mean ± SEM.
*There were no significant differences between the treatment groups for any of the results in Trial 1.
†The low and high dose antioxidant combinations were made up in 0.45% saline with 30% canola oil.
#p < 0.05 before (pre-treat) vs. after (post-treat) treatment, Student’s t-tests.
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had no effect on MBP content (Tables 1 and 2).
In the frontal cortex at the level of the anterior horns
of the lateral ventricles, sham and antioxidant-treated
hydrocephalic rats displayed GFAP immunostaining of
astrocytes in the perivascular and periventricular re-
gions. There were no appreciable differences in GFAP
2expression between the hydrocephalic groups. In com-
parison to nonhydrocephalic controls, all had hyper-
trophic reactive astrocytes in the periventricular white
matter and deep cortical regions. GFAP content, measured
by ELISA, was increased in comparison to nonhydroce-
phalic controls, but there was no evidence that antioxidant
therapy reduced the astroglial reaction (Tables 1 and 2). In
the hindbrain surrounding the site of injection, there were
no obvious inflammatory or reactive changes visible, such
as macrophages, except in the most severe hydrocephalic
rats that had to be sacrificed before the end of the anti-
oxidant treatment (data not shown).
Lipid peroxidation in the parietal cerebrum, measured
with the TBARS assay, was higher in hydrocephalic rats
than in nonhydrocephalic controls. Comparing the four
hydrocephalic treatment groups separately, all except the
dextrose-treated group (p = 0.074) displayed significantly
higher levels of oxidative stress (all p < 0.05) than non-
hydrocephalic controls (Table 2). However, they were not
significantly different from each other (p = 0.926, ANOVA;
t-tests) suggesting that the oral antioxidant therapy had no
beneficial effect.Total antioxidant capacity of the hippocampal tissue,
detected indirectly through the ABTS+ radical cation,
displayed no appreciable differences between nonhydro-
cephalic controls compared to hydrocephalic rats. There
were no significant differences in antioxidant levels be-
tween the four hydrocephalic treatment groups (p = 0.079,
ANOVA); the dextrose-treated group exhibited the lowest
values, but it was not significantly lower than the vehicle-
treated group (p = 0.090, t-test) or nonhydrocephalic
controls (p = 0.150, t-test) (Table 2).Discussion
Hydrocephalus was induced in three-week old rats, and
oral antioxidant therapy was introduced two weeks later
for a period of two weeks. Because oxidative stress oc-
curs in hydrocephalus [3,9-13], it was hoped that anti-
oxidants might have therapeutic benefits for treating
hydrocephalus. The main positive outcome (in trial 2)
was normalization of antioxidant capacity in brain tissue
when hydrocephalic rats were administered canola oil
with or without the antioxidant combination in compari-
son to the hydrocephalic rats that received dextrose.
Canola oil components are known to have potent anti-
oxidative capacity [42]. The dextrose treated rats had the
greatest ventricular enlargement. Overall, however, there
was no other behavioral, histological, or biochemical evi-
dence to support the hypothesis that oral antioxidant
therapy protects the hydrocephalic brain.









Sample size 8 11 10 11 10
Ventricle area index (pre-treat) 0.006 ± 0.0007 0.114 ± 0.013** 0.119 ± 0.016** 0.107 ± 0.015** 0.118 ± 0.015**
Ventricle area index (post-treat) 0.012 ± 0.003 0.140 ± 0.018**# 0.169 ± 0.027**# 0.125 ± 0.013**# 0.140 ± 0.010**#
Percent enlargement ventricles during treatment - 22.5 ± 8.1 40.1 ± 6.2 23.0 ± 6.8 25.1 ± 8.3
Body weight (g) (pre-treat) 169.3 ± 4.6 123.3 ± 7.2** 135.2 ± 8.2** 116.9 ± 6.4** 112.7 ± 5.3**
Body weight (g) (post-treat) 269.3 ± 6.7# 200.2 ± 13.4**# 219.4 ± 13.5*# 175.4 ± 12.5**# 179.6 ± 12.0**#
Rearing activity (post-treat) (beam breaks - 5 min) 100 ± 12 67 ± 12 96 ± 8 78 ± 16 82 ± 16
Ambulatory activity (post-treat) (beam breaks - 5 min) 466 ± 35 334 ± 31*# 548 ± 54# 461 ± 39# 396 ± 53#
Total activity (post-treat) (beam breaks - 5 min) 618 ± 41 459 ± 38*# 713 ± 54# 637 ± 41# 558 ± 53#
Endurance of rotarod (cont. speed, post-treat) (sec) 33 ± 8 32 ± 10 37 ± 7 66 ± 15# 38 ± 11
Endurance of rotarod (accelerating speed, post-treat) (sec) 57 ± 15 56 ± 11# 73 ± 14# 65 ± 13# 71 ± 13#
Morris water maze test (post-treat, 3 trials mean) (sec) 7.67 ± 0.85# 6.98 ± 1.10# 5.89 ± 0.61# 5.15 ± 0.41*# 4.46 ± 0.46**#
Swim time 150 cm (post-treat) (sec) 24.3 ± 6.7 13.4 ± 2.0 20.9 ± 3.4 18.0 ± 3.4# 17.0 ± 3.1
Lateral corpus callosum thickness (μm) 315 ± 16 208 ± 14** 220 ± 20** 220 ± 18** 208 ± 13**
GFAP content (ELISA) frontal cerebrum
(mg GFAP/g protein)
0.68 ± 0.16 1.08 ± 0.19 1.29 ± 0.24 1.11 ± 0.16 1.10 ± 0.25
MBP content (ELISA) frontal cerebrum
(mg MBP/g protein)
2.30 ± 0.26 2.42 ± 0.28 2.91 ± 0.28 2.70 ± 0.35 2.30 ± 0.16
MDA level (TBARS) parietal cerebrum
(μM MDA/g wet tissue)
111.98 ± 10.57 145.32 ± 8.94* 138.99 ± 9.41 146.89 ± 9.67* 141.35 ± 8.45*
ABTS + content (antioxidant capacity)
hippocampus (mM)
0.580 ± 0.029 0.582 ± 0.025 0.467 ± 0.062 0.589 ± 0.019 0.574 ± 0.026
All data are presented as mean ± SEM.
†The low and high dose antioxidant combinations were made up in 0.45% saline with 30% canola oil.
*p < 0.05 control rats vs. hydrocephalic groups, Student’s t-tests or ANOVA with Bonferroni-Dunn post hoc tests for intergroup comparisons.
**p < 0.005 control rats vs. hydrocephalic groups, Student’s t-tests or ANOVA with Bonferroni-Dunn post hoc tests for intergroup comparisons.
#p < 0.05 before (pre-treat) vs. after (post-treat) treatment, Student’s t-tests.
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ent finding in the pharmacological studies conducted in
our lab using the kaolin induction model in rats
[19,20,43-45]. We hoped the antioxidant therapy would
display beneficial outcomes in stabilizing ventricular
expansion or reducing associated brain damage and re-
active changes like the results from Botfield et al. [21]
using decorin treatment in juvenile hydrocephalic rats,
but consistent findings were not observed in the two tri-
als. In the first trial, the high dose antioxidant group ex-
hibited the largest expansion of lateral ventricles overall,
but this was due primarily to 1–2 outliers with severe
ventriculomegaly. The second trial suggests that canola
oil alone might have shown a benefit in reducing or sta-
bilizing ventricular enlargement if the treatment period
had been longer and the ventricles were allowed to reach
a larger size. However, corpus callosum thickness was
significantly reduced in the hydrocephalic rats, suggest-
ing that further ventricular expansion would likely lead
to increased destruction of this important white matter
structure. Regardless, corpus callosum reduction wasnot ameliorated by antioxidant therapy, as opposed to
prior drug trials from this lab showing that magnesium
sulfate and nimodipine treatment of hydrocephalic rats
reduces corpus callosum damage [19,20]. Minocycline-
treated hydrocephalic rats are reported to have signifi-
cantly increased cerebral cortex thickness in some brain
regions compared to untreated rats [46]. Antioxidant
therapy was also not associated with reduced GFAP im-
munoreactivity or content when compared to sham-
treated hydrocephalic rats. However, magnesium sulfate,
decorin, and minocycline have shown capacity to reduce
reactive astrogliosis in hydrocephalic rats [20,21,46]. In
addition, decorin has been shown to decrease activated
microglia, macrophages, and other inflammatory cells
accumulation, along with ventriculomegaly in hydro-
cephalic rats [21]. Astrocytic and microglial reactivity
have also been reduced in rats with cerebral ischemia
using the antioxidants α-lipoic acid and vitamin E [32], so
it is uncertain why these agents, which possess synergistic
effects, were unsuccessful at decreasing the reactive astro-
gliosis in our hydrocephalic rats. Memantine, a non-
Figure 2 Bar graph showing the lateral ventricles to frontal
cerebrum brain area ratios (%) from the MR images for the
nonhydrocephalic control rats compared to the four
hydrocephalic treatment groups before and after antioxidant
therapy. All hydrocephalic groups had significantly enlarged ventricles
compared to the nonhydrocephalic rats before and after treatment. * -
Indicates significant increases in lateral ventricles to brain area ratios
after treatment compared to before at p < 0.05.
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2 weeks by intraperitoneal injection was shown to partially
protect hippocampal neurons in 3-week old rats with
kaolin-induced hydrocephalus, although no behavioral or
ventricle size data were reported [47].
As expected, the current study showed increased oxi-
dative stress in the hydrocephalic rats using the TBARS
assay of lipid peroxidation [41,48]. Although the TBARS
assay has been known to display other TBA reactive sub-
stances, previous studies using experimentally-induced
or inherited hydrocephalus in rats have also shown in-
creased oxidative stress when measuring lipid peroxida-
tion, oxygen free radicals, and/or nitric oxide (NO)
production [3,9-13]. Two studies showed that antioxidant
treatment with intraperitoneal N-acetylcysteine [10] or
epigallocatechin gallate [11] were potentially neuroprotec-
tive by reducing lipid peroxidation levels in cerebral and
periventricular white matter regions, respectively. While
the findings of these studies are promising, it is important
to note that their scope is limited because lipid peroxida-
tion was the only outcome parameter measured. In
addition, no means were employed to confirm induction
of hydrocephalus before antioxidant treatment began. This
all must be taken into consideration when moving to
human clinical trials as these drugs have shown onlymarginal success in rodent models of disease. It is of
particular importance when considering the recommenda-
tions for success in treating neurological diseases, such as
stroke or ischemic change in a clinical setting [49,50].
One potential shortcoming of our experiment was
drug combination chosen. As described in the Introduc-
tion, all of the chosen agents have been effective orally
in some experimental settings. Oral therapy offers longer
periods of exposure, but peak levels are lower than those
that follow parenteral administration. Furthermore, the
extent to which the agents crossed the blood–brain bar-
rier (BBB) is not clear. This is important because the
BBB is generally intact in hydrocephalus [51]. Although
all agents used in our antioxidant combination have
been suggested to be orally efficacious in treating mito-
chondrial and neurodegenerative disorders, there are
conflicting data concerning their ability to enter brain
tissue. Glutathione is known to cross the BBB [36,52].
Zhang et al. [53] indicated that α-tocopherol is not re-
stricted from the brain, while Gonzalez-Perez et al. [32]
suggested that vitamin E and lipoic acid treatment for
cerebral ischemia in rats may have only produced partial
neuroprotective effects because of insufficient levels of
these antioxidants in brain tissue. Oral administration of
CoQ10 has been shown to elevate its levels in rat cere-
bral cortex mitochondria in one study [54], whereas
others reported restricted uptake [31,53,55]. CoQ10
treatment via intraperitoneal injection also failed to
show neuroprotective effects when administered to rats
with induced focal and global ischemia [56]. More
convincing evidence of the pharmacokinetics of CoQ10
was found by Sikorska et al. [57], who showed a complex
of CoQ10 and an α-tocopherol derivative is neuro-
protective in cerebral ischemia.
As noted above, 30% canola oil vehicle alone seemed
to offer some benefit over dextrose therapy. Canola oil
concentration was the same for both low and high dose
antioxidant combinations. This potentially therapeutic
effect could be related to the fact that canola oil augments
entry of dietary vitamins C and E into brain tissue [58], or
due to the potent scavenger 4-vinyl-2,6-dimethoxyphenol
(canolol), which is the most active component in canola
oil [42]. It scavenges both alkylperoxyl radicals (ROO ·)
and peroxynitrite [59]. Peroxynitrite is a potent oxidizing
and nitrating agent, and overproduction of it may be
related to inflammation and neurodegenerative diseases
[60,61]. Nitrite concentration is significantly increased
in hydrocephalic brains [3], and nitric oxide can nitrate
aromatic amino acids possibly through generation of
peroxynitrite [62]. Thus, canolol in canola oil plays
both antinitrosylating and antioxidative roles, which is
more potent than α-tocopherol and vitamin C [42] that
were used in our antioxidant combination. If confirmed
in gyrencephalic species with larger brains, canola therapy
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combination tested here.
It should also be mentioned that in these experiments,
the rats did not exhibit extreme ventriculomegaly over-
all. Consequently, the behavioral deficits were small and
in some cases, there were no differences between control
and hydrocephalic animals whether or not they received
any antioxidant treatment. The behavioral results showed
differences between trials for some of the tasks; this is
likely related to the different rat strain and slightly differ-
ent methods used to obtain the data. Despite this, with the
rotating cylinder and the water maze tasks, there were no
differences among the treatment conditions for both trials,
which all showed improved performance after treatment.
Reduced rearing activity was the only decrement observed
in the hydrocephalic rats, with the exception of the
dextrose-treated group, which paradoxically had the most
severe ventriculomegaly. Perhaps only more severe dam-
age (e.g. longer duration or greater ventriculomegaly) is
associated with measurable behavioral deficits that might
be amenable to pharmacologic intervention. The MBP
content measured by ELISA showed discrepancy between
trials. Possible explanations include the different rat
strains used, slight differences in the age at time of sacri-
fice, and slight differences in the dissection of the dorsal
brain sample, which was done by separate individuals in
the two trials. Regardless, neither trial showed significant
differences between the sham and treatment groups for
MBP content.Conclusions
In summary, we did not find any behavioral, morpho-
logical, or biochemical evidence that oral antioxidant
combination therapy provided appreciable therapeutic
benefit to juvenile rats with kaolin-induced hydro-
cephalus. Potential explanations are the limited entry of
the drugs into brain or the possibility that oxidative
changes in hydrocephalic brains represent an end point
marker of damage rather than the cause of the axonal
damage. It should be noted that the canola oil vehicle
alone did seem to normalize brain tissue antioxidant
capacity and reduce the rate of ventricle enlargement in
comparison to dextrose treatment. This safe and simple
intervention should be confirmed.Abbreviations
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